ReviewSeminars in cancer biology2016
Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy.
Review in Seminars in cancer biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 1 synthesis or guideline pooled it, 337 citations in OpenAlex.
- Phytonutrients and outcomes following breast cancer: a systematic review and meta-analysis of observational studies.JNCI cancer spectrum · 2024Pooled it
- Anticancer Effects of Broccoli Sprout Extract and Sulforaphane Through ROS-Induced MAPK Pathway in Breast Cancer Cells and Xenografts.Antioxidants (Basel, Switzerland) · 2026Article
- Therapeutic role of caveolin family in stem cell fate and development for management of chronic degenerative diseases: A scientometric study to an in-depth review.Journal of advanced research · 2026Review
- Unveiling the antioxidant and anticancer potential of local mediterranean olive and fig extracts against breast cancer.BMC complementary medicine and therapies · 2026Article
- Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential.Biomedicines · 2026Review
- Targeting notch signaling pathway in esophageal cancer: from molecular insights to therapies.Oncology reviews · 2026Review
- ECSCR functions as a potential tumor suppressor in breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Characterization of global research trends and prospects on celastrol, a principal bioactive ingredient ofPharmaceutical biology · 2025Article
- Butein mitigates 5-FU-triggered hepatotoxicity via antioxidant, anti-inflammatory, and anti-apoptotic pathways.Toxicology reports · 2025Article
- Review
- Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.Discover oncology · 2025Review
- E2F7 transcriptionally upregulates SPC24 to mediate aerobic Glycolysis and facilitate stemness of breast cancer.Journal of bioenergetics and biomembranes · 2025Article
- Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications.Cancer pathogenesis and therapy · 2025Review
- Updated Review on Natural Polyphenols: Molecular Mechanisms, Biological Effects, and Clinical Applications for Cancer Management.Biomolecules · 2025Review
- Comprehensive analysis of angiogenesis and stemness-related genes in chemotherapy and immunotherapy of bladder cancer.Biomolecules & biomedicine · 2025Article
- Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies.Medical oncology (Northwood, London, England) · 2025Review
- Cancer stem cells and their role in metastasis.Central European journal of urology · 2025Review
- Advances in antitumor effects of pterostilbene and its derivatives.Future medicinal chemistry · 2025Review
- Phytochemical nanoencapsulation and microfluidics drive gene and tumor microenvironment modulation.Frontiers in pharmacology · 2025Review
- Exploring the Mechanism of Lianqiao Jinbei Decoction Inhibiting HER2-Positive Breast Cancer Based on Network Pharmacology and Experimental Verification.Breast cancer (Dove Medical Press) · 2025Article
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Breast cancer is the most common form of cancer diagnosed in women worldwide and the second leading cause of cancer-related deaths in the USA. Despite the development of newer diagnostic methods, selective as well as targeted chemotherapies and their combinations, surgery, hormonal therapy, radiotherapy, breast cancer recurrence, metastasis and drug resistance are still the major problems for breast cancer. Emerging evidence suggest the existence of cancer stem cells (CSCs), a population of cells with the capacity to self-renew, differentiate and be capable of initiating and sustaining tumor growth. In addition, CSCs are believed to be responsible for cancer recurrence, anticancer drug resistance, and metastasis. Hence, compounds targeting breast CSCs may be better therapeutic agents for treating breast cancer and control recurrence and metastasis. Naturally occurring compounds, mainly phytochemicals have gained immense attention in recent times because of their wide safety profile, ability to target heterogeneous populations of cancer cells as well as CSCs, and their key signaling pathways. Therefore, in the present review article, we summarize our current understanding of breast CSCs and their signaling pathways, and the phytochemicals that affect these cells including curcumin, resveratrol, tea polyphenols (epigallocatechin-3-gallate, epigallocatechin), sulforaphane, genistein, indole-3-carbinol, 3, 3'-di-indolylmethane, vitamin E, retinoic acid, quercetin, parthenolide, triptolide, 6-shogaol, pterostilbene, isoliquiritigenin, celastrol, and koenimbin. These phytochemicals may serve as novel therapeutic agents for breast cancer treatment and future leads for drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.